The role of iron in gray matter degeneration in huntington's disease: A magnetic resonance imaging study

Human Brain Mapping

Volumn 36, Issue 1, 2015, Pages 50-66

  Sánchez Castañeda, Cristina ^a,b   Squitieri, Ferdinando ^c   Di Paola, Margherita ^a,d   Dayan, Michael ^a   Petrollini, Martina ^c   Sabatini, Umberto ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Huntington's disease; Iron; MRI; Multimodal; Neuronal loss

Indexed keywords

HTT PROTEIN, HUMAN; IRON; NERVE PROTEIN;

ADULT; AGED; ANALYSIS OF VARIANCE; BRAIN; CASE CONTROL STUDY; COMPLICATION; DISEASE COURSE; FEMALE; GENETICS; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; MALE; METABOLISM; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SEVERITY OF ILLNESS INDEX; THREE DIMENSIONAL IMAGING; TRINUCLEOTIDE REPEAT;

ADULT; AGED; ANALYSIS OF VARIANCE; BRAIN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GRAY MATTER; HUMANS; HUNTINGTON DISEASE; IMAGING, THREE-DIMENSIONAL; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; SEVERITY OF ILLNESS INDEX; TRINUCLEOTIDE REPEATS;

EID: 84916606763     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22612     Document Type: Article

References (52)

1. Ashburner J, Friston KJ (2000): Voxel-based morphometry-The methods. Neuroimage 11:805-821.
2. Aylward EH (2007): Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 72:152-158.
3. Aylward E, Mills J, Liu D, Nopoulos P, Ross CA, Pierson R, Paulsen JS (2011a): Association between age and striatal volume stratified by CAG repeat length in prodromal Huntington disease. PLoS Curr 3:RRN1235.
4. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, Johnson HJ, Magnotta VA, Juhl AR, Paulsen JS; PREDICT-HD Investigators and Coordinators of Huntington Study Group (2011b): Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 82:405-410.
5. Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Long JD, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2012): Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 71:822-828.
6. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J (1999): Increased basal ganglia iron levels in Huntington disease. Arch Neurol 56:569-574.
7. Bartzokis G, Lu PH, Tishler TA, Fong SM, Oluwadara B, Finn JP, Huang D, Bordelon Y, Mintz J, Perlman S (2007): Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 32:1655-1664.
8. Brinkman RR, Mezei MM, Theilmann J, Almquist E, Hayden MR (1997): The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60:1202-1210.
9. Chen JC, Hardy PA, Kucharczyk W, Clauberg M, Joshi JG, Vourlas A, Dhar M, Henkelman RM (1993): MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 14:275-281.
10. Cherubini A, Péran P, Caltagirone C, Sabatini U, Spalletta G (2009): Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 48:29-36.
11. Dexter DT, Jenner P, Schapira AH, Marsden CD (1992): Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 (Suppl):S94-S100.
12. Di Paola M, Luders E, Cherubini A, Sanchez-Castaneda C, Thompson PM, Toga AW, Caltagirone C, Orobello S, Elifani F, Squitieri F, Sabatini U (2012): Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. Cereb Cortex 22:2858-2866.
13. Douaud G, Behrens TE, Poupon C, Cointepas Y, Jbabdi S, Gaura V, Golestani N, Krystkowiak P, Verny C, Damier P, Bachoud-Lévi AC, Hantraye P, Remy P (2009): In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage 46:958-966.
14. Dumas EM, Versluis MJ, van den Bogaard SJ, van Osch MJ, Hart EP, van Roon-Mom WM, van Buchem MA, Webb AG, van der Grond J, Roos RA; TRACK-HD investigators (2012): Elevated brain iron is independent from atrophy in Huntington's Disease. Neuroimage 61:558-564.
15. Folstein MF, Folstein SE, McHugh PR (1975): Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
16. Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP, Myers RH (2001): Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 49:29-34.
17. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001): A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14:21-36.
18. Han I, You Y, Kordower JH, Brady ST, Morfini GA (2010): Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem 113:1073-1091.
19. Hilditch-Maguire P, Trettel F, Passani L, Auerbach A, Persichetti F, MacDonald ME (2000): Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 9:2789-2797.
20. Huntington Study Group (1996): The unified Huntington's disease rating scale: Reliability and consistency. Mov Dis 11:136-142.
21. Jenkinson M, Bannister P, Brady M, Smith S (2002): Improved optimisation for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:825-841.
22. Kell DB (2010): Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84:825-889.
23. Koeppen AH (2003): A brief history of brain iron research. J Neurol Sci 207:95-97.
24. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004): A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65:267-277.
25. Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, Fazekas F, Ropele S (2010): Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 257:455-462.
26. Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, Sommer K, Reishofer G, Yen K, Fazekas F, Ropele S, Reichenbach JR (2012): Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 62:1593-1599.
27. Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI (2007): Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet 16:1905-1920.
28. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I; Huntington Study Group (2001): Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57:658-662.
29. Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E; Predict-HD Investigators of the Huntington Study Group (2006): Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 63:883-890.
30. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, Nance M; PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG) (2010): Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 82:201-207.
31. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997): CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41:689-692.
32. Péran P, Hagberg G, Luccichenti G, Cherubini A, Brainovich V, Celsis P, Caltagirone C, Sabatini U (2007): Voxel-based analysis of R2* maps in the healthy human brain. J Magn Reson Imaging 26:1413-1420.
33. Péran P, Cherubini A, Luccichenti G, Hagberg G, Démonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, Sabatini U (2009): Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp 30:2667-2675.
34. Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U (2010): Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133:3423-3433.
35. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM (2003): Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology 60:1615-1620.
36. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005): Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65:745-747.
37. Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, Bush A, Fox J, Hersch SM (2012): Alterations in brain transition metals in Huntington disease: An evolving and intricate story. Arch Neurol 69:887-893.
38. Rosenblatt A, Liang KY, Zhou H, Abbott MH, Gourley LM, Margolis RL, Brandt J, Ross CA (2006): The association of CAG repeat length with clinical progression in Huntington's disease, Neurology 66:1016-1020.
39. Sánchez-Castañeda C, Cherubini A, Elifani F, Péran P, Orobello S, Capelli G, Sabatini U, Squitieri F (2013): Seeking huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp 34:1625-1635.
40. Schenck JF, Zimmerman EA (2004): High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 17:433-445.
41. Simmons DA, Casale M, Alcon B, Pham N, Narayan N, Lynch G (2007): Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55:1074-1084.
42. Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH (2011): Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25:1-14.
43. Smith SR, Cooperman S, Lavaute T, Tresser N, Ghosh M, Meyron-Holtz E, Land W, Ollivierre H, Jortner B, Switzer R 3rd, Messing A, Rouault TA (2004): Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci 1012:65-83.
44. Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD (2003): Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain. 126:946-955.
45. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC; TRACK-HD investigators (2009): Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol 8:791-801.
46. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators (2011): Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31-42.
47. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; TRACK-HD investigators (2012): Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42-53.
48. Vonsattel JP (2008): Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115:55-69.
49. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985): Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577.
50. Vymazal J, Klempír J, Jech R, Zidovská J, Syka M, Růzicka E, Roth J (2007): MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters. J Neurol Sci 263:20-25.
51. Walker FO (2007): Huntington's disease. Lancet 369:220-221.
52. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA (2004): The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 101:9843-9848.